Fisons' Pneumopent Treatment IND
Filed on March 30 for prophylaxis of AIDS-related Pheumocystis carinii pneumonia. FDA has until April 30 to respond to treatment protocol. The company also plans to have submitted complete NDA for Pneumopent by May 1 FDA Anti-Infective Drug Products Advisory Committee meeting. Officially, FDA says the advisory committee will only consider Lyphomed's NDA for aerosolized Pentam. However, Fisons will be given the opportunity to present data during the open hearing portion of the meeting.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”